Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | RAMES: ramucirumab + gemcitabine in relapsed mesothelioma patients

Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK discusses the result of the RAMES study (NCT03560973) which was evaluating the addition of ramucirumab, a VEGFR2 inhibitor, to gemcitabine in relapsed mesothelioma patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).